measuring circulating tumor DNA works because of the presence of circulating tumor cells in the blood; the same cannot be said the B-cell lymphoma cells. Another challenge is the genetic heterogeneity ...

Patients must have received ≥2 previous lines of systemic therapy, be ineligible for hematopoietic SCT or CAR T-cell therapy, and have an Eastern Cooperative Oncology Group performance status of ≤2.

The startup was the first company in India to conduct the therapy trials in 2022 for adult patients with relapsed or refractory B-cell non-hodgkin lymphoma ... facing aggressive blood cancers. By ...

and follicular lymphoma. Intense global research is now exploring the clinical potential of CAR T-cell therapies beyond blood cancers, with therapies in development targeting solid tumours, autoimmune ...

MRI scans aren’t ... blood cells. For certain lymphomas that are either aggressive or very slow-growing, surgery may be used to remove the cancer. The type of surgery depends on the type of ...

Because B-cell lymphoma develops in a type of white blood cell, the team examined their precursors, called hematopoietic stem cells, in the mice. Genetically disrupting inflammasome activity in ...

"How endothelial cells migrate is very important because new blood vessels won't form if they fail to migrate. Or if they migrate in a perturbed manner, mispatterned blood vessels can form ...

They discovered that mice missing a type of immune cell called ILC2 couldn’t produce enough glucagon—the hormone that raises blood sugar—and their glucose levels dropped too low.

A new type of cell ... lymphoma, a type of blood cancer. Larger studies are needed to assess efficacy, but early data suggest this approach could offer a less toxic alternative to CAR-T cell ...

Terumo Blood and Cell Technologies (Terumo BCT) and FUJIFILM Irvine Scientific have announced a strategic collaboration to help accelerate T cell expansion using Fujifilm's PRIME-XV ® T Cell ...

A new type of cell ... lymphoma, a type of blood cancer. Larger studies are needed to assess efficacy, but early data suggests that this approach could offer a less toxic alternative to CAR-T ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.